Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Eisenmenger's syndrome presents as a severe clinical picture of polymorbidity that
constitutes a great burden at the individual as well as the familial and social level. The
combination of critically increased pulmonary vascular resistance, progressive pressure load
of the right ventricle and disturbance of pulmonary gas exchange result in long-term
polymorbidity. The objective of this study is to provide evidence of improvement of patients
exercise tolerance as well as general conditions by treatment with oral sildenafil as a
specific pulmonary vasodilator.